Targeting cancer-initiating cell drug-resistance: A Sroadmap to a new-generation of cancer therapies?

Drug Discovery Today

Volumn 17, Issue 9-10, 2012, Pages 435-442

  Alama, Angela ^a   Orengo, Anna Maria ^a   Ferrini, Silvano ^a   Gangemi, Rosaria ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AUROTHIOMALATE; BANOXANTRONE; BMS 833923; CATUMAXOMAB; CYANAMIDE; CYCLOPHOSPHAMIDE; DISULFIRAM; DOCETAXEL; DOFEQUIDAR; DOXORUBICIN; ERISMODEGIB; GEMCITABINE; GIRENTUXIMAB; GLUCONATE COPPER; INDISULAM; METFORMIN; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; PR 104; RAPAMYCIN; RESVERATROL; SARIDEGIB; TARIQUIDAR; TEMOZOLOMIDE; TH 302; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VISMODEGIB; XL 139;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CELL SUBPOPULATION; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HYPOXIA; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUMOR; LIVER TUMOR; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT ASCITES; MELANOMA; METASTASIS; METASTATIC MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SARCOMA; SOLID TUMOR; TREATMENT FAILURE; TUMOR DIFFERENTIATION;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84857144607     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.02.005     Document Type: Review

References (94)

1. T. Lapidot A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
2. M. Al-Hajj Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 3983 3988
3. S.K. Singh Identification of human brain tumour initiating cells Nature 432 2004 396 401
4. P. Dalerba Phenotypic characterization of human colorectal cancer stem cells Proc. Natl. Acad. Sci. U. S. A. 104 2007 10158 10163
5. M.E. Prince Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Proc. Natl. Acad. Sci. U. S. A. 104 2007 973 978
6. S. Zhang Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res. 68 2008 4311 4320
7. P.C. Hermann Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer Stem Cells 1 2007 313 323
8. T. Schatton Identification of cells initiating human melanomas Nature 451 2008 345 349
9. L. Vermeulen Cancer stem cells - old concepts, new insights Cell Death Differ. 15 2008 947 958 Review
10. E. Quintana Efficient tumour formation by single human melanoma cells Nature 456 2008 593 598
11. P.N. Kelly Tumor growth need not be driven by rare cancer stem cells Science 317 2007 337
12. A. Cicalese The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells Cell 138 2009 1083 1095
13. X. Li Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J. Natl. Cancer Inst. 100 2008 672 679
14. A. Yaromina Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies Radiother. Oncol. 81 2006 122 129
15. R. Gangemi Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance Curr. Med. Chem. 16 2009 1688 1703 Review
16. S. Fulda, and S. Pervaiz Apoptosis signaling in cancer stem cells Int. J. Biochem. Cell. Biol. 42 2010 31 38
17. M. Mimeault, and S.K. Batra New promising drug targets in cancer- and metastasis-initiating cells Drug Discov. Today 15 2010 354 364 Review
18. C.A. Rabik Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy Cancer Treat. Rev. 32 2006 261 276 Review
19. J.A. Quinn Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J. Clin. Oncol. 27 2009 1262 1267
20. S. Deng Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers PLoS One 5 2010 e10277
21. J.P. Chute Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells Proc. Natl. Acad. Sci. U. S. A. 103 2006 11707 11712
22. D. Chen Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity Cancer Res. 66 2006 10425 10433
23. A. Ward Flexibility in the ABC transporter MsbA: alternating access with a twist Proc. Natl. Acad. Sci. U. S. A. 104 2007 19005 19010
24. M.M. Ho Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells Cancer Res. 67 2007 4827 4833
25. N. Ban ABCA3 as a lipid transporter in pulmonary surfactant biogenesis J. Biol. Chem. 282 2007 9628 9634
26. M. Haber Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma J. Clin. Oncol. 24 2006 1546 1553
27. J.I. Fletcher ABC transporters in cancer: more than just drug efflux pumps Nat. Rev. Cancer 10 2010 147 156 Review
28. A.F. List Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia J. Clin. Oncol. 11 1993 1652 1660
29. S. Daenen Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults Leuk. Res. 28 2004 1057 1067
30. C. Lhommé Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer J. Clin. Oncol. 26 2008 2674 2682
31. J. Abraham A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine Clin. Cancer Res. 15 2009 3574 3582
32. L. Pusztai Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma Cancer 104 2005 682 691
33. R. Katayama Dofequidar fumarate sensitizes cancer stem-like side population cells chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export Cancer Sci. 100 2009 2060 2068
34. T. Saeki Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer J. Clin. Oncol. 25 2007 411 417
35. P.B. Gupta Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
36. R. Riccioni The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor Blood Cells Mol. Dis. 45 2010 86 92
37. D. Fuchs Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells Biochem. Biophys. Res. Commun. 390 2009 743 749
38. Z. Li Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells Cancer Cell 15 2009 501 513
39. S.A. Mani The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 2009 704 715
40. A. Soeda Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha Oncogene 28 2009 3949 3959
41. Y. Chen Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung Cancer Res. 67 2007 7954 7959
42. D.M. Brown Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin Cancer Res. 53 1993 4633 4636
43. D. Rischin Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group J. Clin. Oncol. 28 2010 2989 2995
44. A.V. Patterson Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA crosslinking agent PR-104 Clin. Cancer Res. 13 2007 3922 3932
45. L.H. Patterson Bioreductively activated antitumor n-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy Drug Metab. Rev. 34 2002 581 592 Review
46. W.P. Steward The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study Ann. Oncol. 18 2007 1099 1103
47. S.R. McKeown Bioreductive drugs: from concept to clinic Clin. Oncol. 19 2007 427 442
48. P. Sansone p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres Stem Cells 25 2007 807 815
49. O.O. Guler Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII Curr. Med. Chem. 2010 1516 1526 Review
50. K.M. Anderson Are cancer stem cells concentrated in more alkaline hypoxic regions of tumors? Med. Hypotheses 74 2010 868 870
51. I.F. Tannock, and D. Rotin Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 49 1989 4373 4384
52. J.E. Surfus Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors J. Immunother. Emphasis Tumor Immunol. 19 1996 184 191
53. T.N. Milovanova Lactate stimulates vasculogenic stem cells via the thioredoxin system and engages an autocrine activation loop involving hypoxia-inducible factor 1 Mol. Cell Biol. 28 2008 6248 6261
54. J. Ceccarelli The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants Int. J. Cancer 123 2008 1770 2177
55. G. Powis The role of the redox protein thioredoxin in cell growth and cancer Free Radical Biol. Med. 29 2000 312 322
56. S. Li Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302 Biol. Trace Elem. Res. 136 2010 294 301
57. J. Duan Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs J. Med. Chem. 51 2008 2412 2420
58. T. Schatton, and M.H. Frank Antitumor immunity and cancer stem cells Ann. N. Y. Acad. Sci. 1176 2009 154 169
59. A. Wu Glioma cancer stem cells induce immunosuppressive macrophages/microglia Neuro. Oncol. 12 2010 1113 1125
60. T. Schatton Modulation of T-cell activation by malignant melanoma initiating cells Cancer Res. 70 2010 697 708
61. J. Wei Glioma-associated cancer-initiating cells induce immunosuppression Clin. Cancer Res. 16 2010 461 473
62. P. Went Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers Br. J. Cancer 94 2006 128 135
63. S.B. Keysar, and A. Jimeno More than markers: biological significance of cancer stem cell-defining molecules Mol. Cancer Ther. 9 2010 2450 2457
64. L.M. Smith CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers Br. J. Cancer 99 2008 100 109
65. A. Salnikov Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma J. Cell. Mol. Med. 13 2009 4023 4033
66. J. Shen, and Z. Zhu Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer Curr. Opin. Mol. Ther. 10 2008 273 284
67. M.A. Ströhlein Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis J. Exp. Clin. Cancer Res. 28 2009 18 28
68. Dick, J. et al. University Health Network. (2007) Patent US2007237761.
69. Young, D. et al. Arius Research Inc. (2007) Patent WO2007098571.
70. H. Riechelmann Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma Oral Oncol. 44 2008 823 829
71. M. Koppe Safety, pharmacokinetics, immunogenicity and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer Cancer Biother. Radiopharm. 19 2004 720 729
72. B.M. Tijink A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus Clin. Cancer Res. 12 2006 6064 6072
73. C.H. Wang Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody Nanomedicine 2010 doi:10. 1016/j. nano. 2010. 06.010
74. M.G. Francipane Crucial role of interleukin-4 in the survival of colon cancer stem cells Cancer Res. 68 2008 4022 4025
75. M. Todaro Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4 Cell Stem Cell. 1 2007 389 402
76. H. Wang Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth Stem Cells 27 2009 2393 2404
77. E. Gorelik Lung cancer stem cells as a target for therapy Anticancer Agents Med. Chem. 10 2010 164 171
78. C. Ginestier CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts J. Clin. Invest. 120 2010 485-497
79. M.K. Wendt Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression Oncogene 2010 doi: 10. 1038/onc. 2010.377
80. S.T. Buckley Differential susceptibility to epithelial-mesenchymal transition (EMT) of alveolar, bronchial and intestinal epithelial cells in vitro and the effect of angiotensin II receptor inhibition Cell Tissue Res. 342 2010 39 51
81. Z. Xu TGFβ and EGF synergistically induce a more invasive phenotype of epithelial ovarian cancer cells Biochem. Biophys. Res. Commun. 401 2010 376 381
82. S. Ohashi Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors Cancer Res. 70 2010 4174 4184
83. L. Caja The transforming growth factor-beta (TGF-β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells J. Cell Physiol. 2010 doi: 10.1002/jcp.22439
84. A.D. Yang Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells Cancer Res. 66 2006 46 51
85. E.J. Giannoni Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness Cancer Res. 70 2010 6945 6956
86. G. Zheng Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells Am. J. Pathol. 175 2009 580 591
87. O. Gonzalez-Moreno VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop Exp. Cell Res. 316 2010 554 567
88. K.S. Chae Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions Oncogene 2010 doi: 10.1038/onc. 2010.498
89. N. Ahmed HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors Clin. Cancer Res. 16 2010 474 485
90. C. Visus Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8 + T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck Cancer Res. 67 2007 10538 10545
91. M. Todaro Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes J. Immunol. 182 2009 7287 7296
92. F. Dieli Targeting human {gamma}{delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer Cancer Res. 67 2007 7450 7457
93. F. Cabillic Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients Cancer Immunol. Immunother. 59 2010 1611 1619
94. P.E. Fecci The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors J. Neurooncol. 64 2003 161 176